Neurotech International (NTI) Stock Overview
A clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NTI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Neurotech International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.029 |
| 52 Week Low | AU$0.01 |
| Beta | 0.033 |
| 1 Month Change | 8.33% |
| 3 Month Change | 0% |
| 1 Year Change | -13.33% |
| 3 Year Change | -67.50% |
| 5 Year Change | -75.47% |
| Change since IPO | -95.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTI | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -13.3% | 0.3% | -0.9% |
| 1Y | -13.3% | -43.8% | 2.3% |
Return vs Industry: NTI exceeded the Australian Medical Equipment industry which returned -43.8% over the past year.
Return vs Market: NTI underperformed the Australian Market which returned 2.3% over the past year.
Price Volatility
| NTI volatility | |
|---|---|
| NTI Average Weekly Movement | 13.0% |
| Medical Equipment Industry Average Movement | 10.0% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: NTI's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: NTI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Anthony Filippis | neurotechinternational.com |
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices.
Neurotech International Limited Fundamentals Summary
| NTI fundamental statistics | |
|---|---|
| Market cap | AU$17.13m |
| Earnings (TTM) | -AU$3.85m |
| Revenue (TTM) | AU$7.07m |
Is NTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTI income statement (TTM) | |
|---|---|
| Revenue | AU$7.07m |
| Cost of Revenue | -AU$1.47m |
| Gross Profit | AU$8.55m |
| Other Expenses | AU$12.40m |
| Earnings | -AU$3.85m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0029 |
| Gross Margin | 120.85% |
| Net Profit Margin | -54.45% |
| Debt/Equity Ratio | 0% |
How did NTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/28 07:17 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurotech International Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Goodsall | MST Financial Services Pty Limited |